INVESTOR RELATIONS
Grounded in Practical R&D Services, Driven by Scalable Biomedical Platforms
Bios Biotech Co., Ltd. combines a resilient foundation of research reagents and specialized laboratory services with high-potential R&D platforms in regenerative biology and human/veterinary rapid test co-development.
Consistent Institutional Demand
Academic laboratories, teaching hospitals, and veterinary researchers maintain steady demand for trace DNA purification, standardized telomere analysis, and expert experimental troubleshooting.
Cross-Domain Platform Scalability
Our core nucleic acid handling and rapid assay engineering platforms apply across both human biomedical research and companion/livestock animal health studies.
Capital-Efficient, Partner-Aligned R&D
Guided by 'Make it easier', our co-development model aligns R&D investment directly with validated partner needs and real-world research applications.
Investor Relations & Strategic Partnership Contact
We welcome biotechnology investors and strategic industry partners to connect with us directly to learn more about our long-term roadmap.
Email：[email protected]｜ Phone: 02-27133289
The information on this page is provided solely to introduce the corporate vision and technology platforms of Bios Biotech Co., Ltd. It does not constitute a public offering, solicitation, or guarantee of financial return. For investor relations and strategic partnership inquiries, please contact us directly.